Finch Therapeutics Group, Inc. announced that it has entered into a clinical trial agreement with Brigham and Women's Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis. The Company also announced updates to its license agreement with the University of Minnesota. Under the clinical trial agreement, Brigham and Women's Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 in patients with mild-to-moderate ulcerative colitis.

the study is designed to generate data on safety, pharmacokinetics, pharmacodynamics and clinical efficacy, and aims to build on a growing body of evidence supporting the role of the microbiome in improving outcomes for patients suffering from ulcerative colitis. Topline data from this clinical study is anticipated in 2025. A key feature of the amendment allows Finch to satisfy certain performance milestones through sublicensing agreements, aligning with Finch's new strategic focus on collaborations and partnerships.